Pfizer Moo’ved To Split Off Zoetis Business By July 2013
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer begins the process to split off its animal health business with an IPO in an effort to save on taxes and refrain from diluting the current shareholder base.
You may also be interested in...
Investors Crow For Shares Of Zoetis As It Begins Trading On The NYSE
Zoetis makes its debut on the public stock exchange, garnering the highest priced IPO since Facebook began trading last year.
No Near-Term Separations For Pfizer, But Business Model Will “Evolve”
Beyond the sale of its nutritionals business and spin-out of animal health into Zoetis, no additional separations are planned for Pfizer in the near-term. But CEO Ian Read discussed how he sees the company’s Established Products and Emerging Markets businesses evolving over the long-term, including the potential for an eventual breakout, during a year-end financial call Jan. 29.
No Near-Term Separations For Pfizer, But Business Model Will “Evolve”
Beyond the sale of its nutritionals business and spin-out of animal health into Zoetis, no additional separations are planned for Pfizer in the near-term. But CEO Ian Read discussed how he sees the company’s Established Products and Emerging Markets businesses evolving over the long-term, including the potential for an eventual breakout, during a year-end financial call Jan. 29.